John Bell
AstraZeneca
13 Papers
26 Citations
John Bell is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Agonist. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated.
Sam Jackson,Albert Candia,Stephen Delaney,Simone Floettmann,Clifford Wong,John D. Campbell,Sariah A. Kell,Jeremy A. Lum,Edith M. Hessel,Paula Traquina,Mark McHale,Ian Robinson,John Bell,Rainard Fuhr,David J. Keeling,Robert L. Coffman +15 more
TL;DR: Nonclinical data and phase I clinical profile of an inhaled TLR9 agonist, AZD1419, a C‐type CpG designed to induce interferon in the lung support its continued development as a potentially disease‐modifying therapeutic in asthma.
24
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme
Christer Janson,Ekaterina Maslova,Alexander Wilkinson,Erika Penz,Alberto Papi,Nigel Budgen,Claus Vogelmeier,Maciej Kupczyk,John Bell,Andrew Menzies-Gow +9 more
TL;DR: In this article , the authors examined the global carbon footprint of its operations and treatment pathways to identify targets for decarbonisation and proposed treatment guidelines to reduce the unmet need in respiratory care by improving disease control and reducing reliever overuse.
21
Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study.
Alexander Wilkinson,E. Maslova,Christer Janson,Vasanth Radhakrishnan,J. Quint,Nigel Budgen,Trung N. Tran,Yang Xu,A. Menzies-Gow,John Bell +9 more
TL;DR: The CARBON study estimated greenhouse gas emissions associated with suboptimal asthma care in the UK, finding that poorly controlled asthma generates significantly higher emissions than well-controlled asthma.
15
S26 An assessment of short-acting β2-agonist (SABA) use and subsequent greenhouse gas (GHG) emissions in five European countries and the consequence of their potential overuse for asthma in the UK
TL;DR: Implementing guidelines to drive improvements in asthma care would improve asthma control, thereby reducing reliever medication use and exacerbation frequency, benefiting patients and realising carbon savings that go beyond the reduction in SABA use alone.
14
Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approach
TL;DR: These studies are the first to evaluate safety of an inhaled TLR7 agonist and demonstrate AZD8848 is safe with a no observed adverse effect level at 26 &mgr;g/kg allowing progression to man with weekly inhalation dosing.
11